Zacks Investment Research
27 Oct 2026, 13:50 UTC · 1h ago
Impact · against what's priced in
Kiniksa Pharmaceuticals (KNSA) showed strong growth with a 75% earnings beat and a 58% year-over-year revenue increase. This suggests a significant acceleration in financial performance compared to analyst expectations.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Kiniksa Pharmaceuticals reported Q3 earnings of $0.56 per share, exceeding the Zacks Consensus Estimate of $0.32 per share.
Newpublished 2026-10-27, mentions 'came out with'
So whatThe 75% surprise represents a significant jump from the $0.30 EPS delivered in the previous quarter.
More positive than 93% of claims this week
The company posted Q3 revenues of $285.97 million, surpassing the Zacks Consensus Estimate by 10.19%.
Continue reading
5 related stories
The company delivered a substantial earnings surprise of $0.56 per share against an estimate of $0.32, and revenue of $285.97 million, representing strong year-over-year growth.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Newpublished 2026-10-27, mentions 'posted revenues'
So whatRevenue grew 58.1% year-over-year compared to the $180.85 million reported in the same period last year.
More positive than 86% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company reported a significant earnings beat of 75% and revenue that surpassed consensus estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
+17.6%
Price agrees with the score
$85.86 vs $72.98 close before publication (Oct 26) · not market-adjusted
KNSA chart →
